Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Defective transcription elongation in a subset of cancers confers immunotherapy resistance (B16 ChIP-Seq)

ABSTRACT: Defective transcription elongation in a subset of cancers confers immunotherapy resistance (B16 ChIP-Seq)

PROVIDER: PRJNA489893 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7807511_1.fastq.gz	Fastqsanger.gz
	SRR7807511_2.fastq.gz	Fastqsanger.gz
	SRR7807512_1.fastq.gz	Fastqsanger.gz
	SRR7807512_2.fastq.gz	Fastqsanger.gz
	SRR7807513_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Defective transcription elongation in a subset of cancers confers immunotherapy resistance (B16 RNA-Seq)

Project description:Defective transcription elongation in a subset of cancers confers immunotherapy resistance (B16 RNA-Seq)

| PRJNA489889 | ENA

Defective transcription elongation in a subset of cancers confers immunotherapy resistance

Project description:Defective transcription elongation in a subset of cancers confers immunotherapy resistance

| PRJNA489885 | ENA

Defective transcription elongation in a subset of cancers confers immunotherapy resistance (human ChIP-Seq)

Project description:Defective transcription elongation in a subset of cancers confers immunotherapy resistance (human ChIP-Seq)

| PRJNA489890 | ENA

Defective transcription elongation in a subset of cancers confers immunotherapy resistance (BGI12 RNA-Seq)

Project description:Defective transcription elongation in a subset of cancers confers immunotherapy resistance (BGI12 RNA-Seq)

| PRJNA489891 | ENA

Defective transcription elongation in a subset of cancers confers immunotherapy resistance (B16 ChIP-Seq)

Project description:The nature and the role of global transcriptional deregulations in cancers are not fully understood. We report a phenotype in a significant portion of cancers characterized by widespread defects in mRNA transcription elongation (TE). Cancers with TE defects (TEdeff) were characterized by spurious transcription and defective mRNA processing, specifically in a large set of genes characterized by long genomic length, poised promoters and inducible expression. As such, signaling pathways regulated by such genes, such as interferon/JAK/STAT and TNF/NF-κB pathways, were consistently suppressed in TEdeff tumors. Remarkably, TEdeff significantly correlated with the poor response and outcome in immunotherapy, but not chemo- or targeted therapy, -treated renal cell carcinoma and metastatic melanoma patients in 4 different cohorts. Importantly, forced pharmacologic or genetic induction of TEdeff in tumor cells impaired the expression of the interferon/JAK/STAT and TNF/NF-κB pathways, and imposed resistance to the innate and adaptive anti-tumor immune responses and checkpoint inhibitor therapy in vivo. Therefore, defective TE is a novel epigenetic mechanism in the tumor arsenal of immune resistance tools, which warrants its assessment in cancer patients undergoing immunotherapy.

2018-09-08 | GSE119677 | GEO